Abstract
Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve outcome. This review discusses the pharmacological attempts at treatment optimisation, which include reducing interindividual pharmacokinetic and pharmacodynamic variability, optimising schedule, route of administration, reversing drug resistance and the development of structurally related second-generation taxanes
Original language | English |
---|---|
Pages (from-to) | 173-177 |
Journal | British journal of cancer |
Volume | 93 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2005 |